Get the Stockscreener App
24.85
0.32%
-0.06
Moderna Inc stock is traded at $24.85, with a volume of 1.57M.
It is down -0.32% in the last 24 hours and down -12.85% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$24.91
Open:
$24.725
24h Volume:
1.57M
Relative Volume:
0.15
Market Cap:
$9.66B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-2.8465
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
-2.05%
1M Performance:
-12.85%
6M Performance:
-10.07%
1Y Performance:
-53.62%
1-Day Range:
$24.50
$24.95
1-Week Range:
$24.25
$29.20
52-Week Range:
$23.15
$56.70
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
24.82 | 9.73B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
414.31 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.71 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
427.62 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
836.93 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.65 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Should You Buy Moderna Stock Ahead of Q3 Earnings Report? - Yahoo! Finance Singapore
17,216 Shares in Moderna, Inc. $MRNA Purchased by Corton Capital Inc. - MarketBeat
Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - USA Today
Nisa Investment Advisors LLC Sells 23,279 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Inc. Stock Slides 8.3%, Underperforms Peers - 富途牛牛
Inside Biotech: Moderna opens new front in oncology with T-cell engager therapy - Proactive financial news
Moderna Stock Is Sliding Monday: What's Going On? - Benzinga
Moderna Stock Falls on Revenue Decline and Clinical Trial SetbackNews and Statistics - IndexBox
Why Moderna (MRNA) Stock Is Falling Today - TradingView
Moderna (MRNA) Begins Phase 1/2 Trial for mRNA-2808 in Multiple Myeloma - GuruFocus
Moderna begins first patient dosing in multiple myeloma trial - Investing.com
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma - Tacoma News Tribune
Moderna (NASDAQ: MRNA) starts Phase 1/2 trial dosing mRNA-2808 for multiple myeloma - Stock Titan
Can Moderna Inc. stock hit record highs again2025 Short Interest & Safe Swing Trade Setup Alerts - newser.com
Moderna, Inc. $MRNA Shares Sold by South Dakota Investment Council - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Is it too late to sell Moderna Inc.2025 AllTime Highs & Weekly Top Gainers Trade List - newser.com
Is Moderna Inc. stock in correction or buying zoneAnalyst Upgrade & Risk Controlled Daily Trade Plans - newser.com
Will Moderna Inc. stock benefit from sector rotationPortfolio Risk Summary & Fast Entry Momentum Alerts - newser.com
Moderna Stock Soars 13.93%, Hits Intraday High of $29.20 - Markets Mojo
GAM Holding AG Invests $276,000 in Moderna, Inc. $MRNA - MarketBeat
Wealthfront Advisers LLC Has $521,000 Stake in Moderna, Inc. $MRNA - MarketBeat
New York Life Investment Management LLC Acquires 31,327 Shares of Moderna, Inc. $MRNA - MarketBeat
Applying Wyckoff theory to Moderna Inc. stock2025 Market WrapUp & Scalable Portfolio Growth Ideas - newser.com
Moderna’s Mysterious Exit Sparks Acquisition Frenzy—What’s Really Happening? - Smartkarma
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025 - York Dispatch
Y Intercept Hong Kong Ltd Makes New Investment in Moderna, Inc. $MRNA - MarketBeat
Sumitomo Mitsui Trust Group Inc. Trims Holdings in Moderna, Inc. $MRNA - MarketBeat
Asset Management One Co. Ltd. Reduces Stock Position in Moderna, Inc. $MRNA - MarketBeat
How Moderna Inc. stock benefits from tech adoptionJuly 2025 Catalysts & Detailed Earnings Play Strategies - newser.com
Moderna (NASDAQ:MRNA) Stock Price Up 9.5%Time to Buy? - MarketBeat
Moderna Stock Falls, Reversing Some Buyout Rally Gains | 2025News and Statistics - IndexBox
Why Moderna (MRNA) Stock Is Trading Lower Today - Yahoo Finance
Moderna: Focus On Cancer Vaccines, Not Buyout (NASDAQ:MRNA) - Seeking Alpha
Moderna (MRNA) Stock Is Trading Lower Friday: What's Going On?Moderna (NASDAQ:MRNA) - Benzinga
Moderna (MRNA) Stock Retreats After Acquisition Speculation Surge - GuruFocus
Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Best data tools to analyze Moderna Inc. stockWeekly Stock Report & Precise Buy Zone Identification - newser.com
Why Moderna Inc. stock is favored by top institutions2025 Stock Rankings & Daily Entry Point Trade Alerts - newser.com
Strength Seen in Moderna (MRNA): Can Its 13.9% Jump Turn into More Strength? - Nasdaq
Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline - sharewise.com
Is Moderna Inc. meeting your algorithmic filter criteriaJuly 2025 PreEarnings & Low Risk High Reward Ideas - newser.com
Will Moderna Inc. stock gain from strong economyWeekly Profit Summary & Safe Capital Investment Plans - newser.com
Using Ichimoku Cloud for Moderna Inc. technicalsForecast Cut & Daily Profit Focused Screening - newser.com
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans - columbiadailyherald.com
Moderna Ignites Biotech Sector with Deal Talk Surge Amidst Broader Healthcare Woes - FinancialContent
S&P 500 Gains and Losses Today: Meta Stock Drops After Earnings; Moderna Surges - Investopedia
Moderna (MRNA) Stock Rallies on Rumors of Potential Takeover Deal - parameter.io
Moderna Stock Rallies On Reports Of Company Entering Talks With A Drugmaker For A Potential Deal - Stocktwits
Moderna soars after STAT reports “a buyout or a large partnership” are on the table - Sherwood News
Moderna to Present at Upcoming Conferences in September 2025 - Iowa City Press-Citizen
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
1.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):